Allergan's Sanctions Bill 'Unreasonable,' Imprimis Says
The "unreasonable and excessive" fees Allergan USA Inc. is requesting from Imprimis Pharmaceuticals Inc. for that company's failure to comply with discovery orders in a closely watched false advertising suit came...To view the full article, register now.
Already a subscriber? Click here to view full article